| Literature DB >> 26621566 |
Teruhisa Tanaka, Tetsuo Hirata, Gretchen Parrott, Miwa Higashiarakawa, Takeshi Kinjo, Tetsu Kinjo, Akira Hokama, Jiro Fujita.
Abstract
This study evaluated the prevalence of Strongyloides stercoralis infection and human T-cell lymphotropic virus type 1 (HTLV-1) infection in the population. In addition, this study investigated the relationship between S. stercoralis infection or HTLV-1 infection and a patient's risk of developing related cancers. This is a retrospective cohort study of 5,209 patients. The prevalence of S. stercoralis infection was 5.2% among all patients. The prevalence among men (6.3%) was significantly higher than among women (3.6%, P < 0.001). The prevalence of HTLV-1 infection among this population was 13.6% and the prevalence among women (15.5%) was significantly higher than that of men (12.3%, P < 0.001). HTLV-1 seroprevalence was higher in patients with liver cancer (P = 0.003, odds ratio [OR]: 1.91, 95% confidence interval [CI]: 1.24, 2.95) and in those with lymphoma other than adult T-cell leukemia/lymphoma (ATLL) (P = 0.005, adjusted OR: 2.76, 95% CI: 1.36, 5.62) if compared with patients without any neoplasm. The prevalence of both S. stercoralis and HTLV-1 in the Okinawan population has been steadily decreasing over the past 24 years. HTLV-1 infection significantly increases the odds of developing liver cancer and lymphomas other than ATLL. © The American Society of Tropical Medicine and Hygiene.Entities:
Mesh:
Year: 2015 PMID: 26621566 PMCID: PMC4751948 DOI: 10.4269/ajtmh.15-0556
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
Patient characteristics (N = 5,209)
| Men | 3,154 (60.5%) |
| Age | 56.4 (SD: 17.9) range: 11–101 years |
| Cancers | |
| Esophagus | 114 (2.2%) |
| Stomach | 262 (5.0%) |
| Biliary tract | 71 (1.4%) |
| Liver | 143 (2.7%) |
| Colon and rectum | 200 (3.8%) |
| Lung | 444 (8.5%) |
| Pancreas | 38 (0.7%) |
| Lymphoma without ATLL | 42 (0.8%) |
| Others | 171 (3.3%) |
ATLL = adult T-cell leukemia/lymphoma; SD = standard deviation.
Other cancers include breast cancer, uterine cancer, kidney cancer, pharyngeal and laryngeal cancer, and ATLL, among others.
Prevalences of Strongyloides stercoralis infection and HTLV-1 infection
| Birth year | Number of | Number of HTLV-1 positive patients/number of tested patients (%) | ||||
|---|---|---|---|---|---|---|
| Men | Women | Total | Men | Women | Total | |
| ≤ 1919 | 24/168 (14.8) | 14/106 (13.2) | 38/274 (13.9) | 31/168 (18.5) | 29/106 (27.3) | 60/274 (21.9) |
| 1920–1929 | 59/526 (11.2) | 22/326 (6.7) | 81/852 (9.5) | 83/526 (15.8) | 77/326 (23.6) | 160/852 (18.8) |
| 1930–1939 | 76/794 (9.6) | 27/500 (5.4) | 103/1,294 (8.0) | 141/794 (17.8) | 112/500 (22.4) | 253/1,294 (19.6) |
| 1940–1949 | 33/522 (6.3) | 8/365 (2.2) | 41/887 (4.6) | 66/522 (12.6) | 54/365 (14.8) | 120/887 (13.5) |
| 1950–1959 | 7/449 (1.6) | 2/300 (0.7) | 9/749 (1.2) | 38/449 (8.5) | 26/300 (8.7) | 64/749 (8.5) |
| 1960–1969 | 0/331 (0.0) | 0/207 (0.0) | 0/538 (0.0) | 23/331 (6.9) | 13/207 (6.3) | 36/538 (6.7) |
| 1970–1979 | 0/251 (0.0) | 0/163 (0.0) | 0/414 (0.0) | 6/251 (2.4) | 8/163 (4.9) | 14/414 (3.4) |
| 1980–1989 | 0/88 (0.0) | 0/72 (0.0) | 0/160 (0.0) | 1/88 (1.1) | 0/72 (0.0) | 1/160 (0.6) |
| ≥ 1990 | 0/25 (0.0) | 0/16 (0.0) | 0/41 (0.0) | 0/25 (0.0) | 0/16 (0.0) | 0/41 (0.0) |
| Total | 199/3,154 (6.3) | 73/2,055 (3.6) | 272/5,209 (5.2) | 389/3,154 (12.3) | 319/2,055 (15.5) | 708/5,209 (13.6) |
HTLV-1 = human T-cell lymphotropic virus type 1.
P < 0.001 for male vs. female by χ2 analysis.
Figure 1.The study included 5,209 patients who were admitted to the First Department of Internal Medicine for Infectious, Respiratory, and Digestive Medicine at the University of Ryukyus Hospital in Okinawa, Japan, between 1991 and 2014. (A) The prevalence of Strongyloides stercoralis infection in men (circles) and women (squares) by age. (B) The prevalence of human T-cell lymphotropic virus type 1 infection in the men (circles) and women (squares) by age.
Crude analysis (all cases and controls born before 1960)
| HTLV-1 | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Positive | 82 (2.0%) | 190 (4.7%) | 272 | |
| Negative | 575 (14.2%) | 3,209 (79.1%) | 3,784 | |
| Total | 657 | 3,399 | 4,056 | |
HTLV-1 = human T-cell lymphotropic virus type 1.
Odds ratio = 2.41 (95% confidence interval = 1.83, 3.17; P < 0.001) by χ2 analysis.
Gender-stratified analyses
| HTLV-1 | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Men | ||||
| Positive | 48 (2.0%) | 151 (6.1%) | 199 | |
| Negative | 311 (12.6%) | 1,949 (79.3%) | 2,260 | |
| Total | 359 | 2,100 | 2,459 | |
| Women | ||||
| Positive | 34 (2.1%) | 39 (2.4%) | 73 | |
| Negative | 264 (16.5%) | 1,260 (78.9%) | 1,524 | |
| Total | 298 | 1,299 | 1,597 | |
HTLV-1 = human T-cell lymphotropic virus type 1.
Odds ratio (OR) = 1.99 (95% confidence interval (CI) = 1.41, 2.82; P < 0.001) by χ2 analysis.
OR = 4.16 (95% CI = 2.58, 6.72; P < 0.001) by χ2 analysis.
Association between Strongyloides stercoralis infection and each cancer type (patients born before 1960, N = 4,056)
| Stratified analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| OR | 95% CI | ||||
| Control | 5.7% (147/2,596) | ||||
| Total cancer | 8.7% (117/1,352) | < 0.001 | 1.28 | 0.98–1.66 | 0.06 |
| Esophagus | 6.4% (7/109) | 0.48 | 0.65 | 0.29–1.45 | 0.29 |
| Stomach | 9.9% (24/242) | 0.45 | 1.22 | 0.76–1.97 | 0.42 |
| Biliary tract | 14.5% (10/69) | 0.05 | 1.90 | 0.93–3.87 | 0.08 |
| Liver | 6.4% (9/140) | 0.43 | 0.72 | 0.35–1.47 | 0.37 |
| Colon and rectum | 7.7% (15/194) | 0.68 | 0.94 | 0.53–1.66 | 0.82 |
| Lung | 9.6% (40/418) | 0.46 | 1.09 | 0.73–1.64 | 0.68 |
| Pancreas | 5.4% (2/37) | 0.77 | 0.83 | 0.19–3.55 | 0.80 |
| Lymphoma without ATLL | 2.7% (1/37) | 0.37 | 0.28 | 0.28–2.08 | 0.21 |
ATLL = adult T-cell leukemia/lymphoma; CI = confidence interval; OR = odds ratio.
A χ2 analysis was used to compare S. stercoralis infection between patients with cancer (total cancer) and control patients (control).
A χ2 analysis was used to compare S. stercoralis infection between patients with each type of cancer and patients with other types of cancer.
A logistic regression analysis, adjusted for age and sex, was used to compare S. stercoralis infection between patients with cancer (total cancer) and control patients (control).
A logistic regression analysis, adjusted for age and sex, was used to compare S. stercoralis infection between patients with each type of cancer and patients with other types of cancer.
Association between HTLV-1 infection and each cancer type (patients born before 1990, N = 5,168)
| Stratified analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| HTLV-1 infection rate | OR | 95% CI | |||
| Control | 12.9% (467/3,612) | – | – | – | – |
| Total cancer | 15.2% (219/1,437) | 0.03 | 0.90 | 0.75–1.09 | 0.28 |
| Esophagus | 8.8% (10/114) | 0.06 | 0.56 | 0.29–1.11 | 0.10 |
| Stomach | 12.2% (32/262) | 0.15 | 0.75 | 0.50–1.12 | 0.16 |
| Biliary tract | 16.9% (12/71) | 0.73 | 0.96 | 0.53–1.84 | 0.90 |
| Liver | 22.3% (32/143) | 0.01 | 1.91 | 1.24–2.95 | 0.003 |
| Colon and rectum | 15.0% (30/200) | 1.00 | 0.91 | 0.60–1.40 | 0.68 |
| Lung | 13.5% (60/444) | 0.23 | 0.81 | 0.58–1.12 | 0.19 |
| Pancreas | 7.8% (3/38) | 0.26 | 0.45 | 0.14–1.49 | 0.19 |
| Lymphoma without ATLL | 28.5% (12/42) | 0.03 | 2.76 | 1.36–5.62 | 0.005 |
ATLL = adult T-cell leukemia/lymphoma; HTLV-1 = human T-cell lymphotropic virus type 1; CI = confidence interval; OR = odds ratio.
A χ2 analysis was used to compare HTLV-1 infection between patients with cancer (total cancer) and control patients (control).
A χ2 analysis was used to compare HTLV-1 infection between patients with each type of cancer and patients with other types of cancer.
A logistic regression analysis, adjusted for age and sex, was used to compare HTLV-1 infection between patients with cancer (total cancer) and control patients (control).
A logistic regression analysis, adjusted for age and sex, was used to compare HTLV-1 infection between patients with each type of cancer and patients with other types of cancer.